Literature DB >> 14613270

Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation.

Alexander Fraser1, Ursula Fearon, R Clark Billinghurst, Mirela Ionescu, Richard Reece, Thomas Barwick, Paul Emery, A Robin Poole, Douglas J Veale.   

Abstract

OBJECTIVE: To determine in vivo the extent of damage to, and changes in turnover of, articular cartilage type II collagen (CII) and the proteoglycan aggrecan following the onset of inflammatory arthritis in humans, and to examine the hypothesis that there are direct relationships between cartilage biomarkers of damage/turnover and clinical, histologic, and molecular markers of inflammation.
METHODS: Synovial fluid (SF) and synovial membrane (SM) were obtained by arthroscopy, and a synovitis score was determined, in 32 patients with rheumatoid arthritis (RA) (13 with early untreated disease, 19 with established disease), 18 with psoriatic arthritis (PsA), and 10 with osteoarthritis (OA). Systemic disease activity markers were recorded, and SM CD3+ T cells, CD4+ T cells, CD68+ macrophages, and lining layer hyperplasia were quantified. SF levels of tumor necrosis factor alpha (TNFalpha), interleukin-10 (IL-10), matrix metalloproteinase 1 (MMP-1), MMP-3, Col2-3/4C(Long mono) neoepitope (C2C) (reflecting collagenase cleavage of cartilage CII), C-propeptide of type II procollagen (PIICP) (a biosynthesis marker), keratan sulfate (KS), and the 846 epitope of aggrecan (turnover) were measured by enzyme-linked immunosorbent assay or radioimmunoassay.
RESULTS: Levels of cartilage degradation products in early RA or early PsA were not elevated above levels in OA, although in early inflammatory arthritis, TNFalpha and MMP-1 levels were similar to those observed in late inflammatory disease and higher than those in OA. PIICP was reduced in early RA. Correlations were observed between the SF C2C neoepitope level and the Health Assessment Questionnaire score, C-reactive protein level, plasma viscosity, synovitis score, and SF TNFalpha and MMP-1 levels. KS epitope content was reduced in direct relation to SM macrophage infiltration in the sublining and lining layers and in the presence of elevated SF MMP-3. Both SF MMP-1 and SF MMP-3 levels correlated with CD4+ T cell infiltration and lining layer hyperplasia in the SM, and MMP-1 levels correlated with lining layer CD68 levels, but TNFalpha and IL-10 levels did not.
CONCLUSION: Except for CII synthesis, there were no significant changes in extracellular matrix turnover of aggrecan or CII in the early stages of human inflammatory arthritis. However, the direct correlation between the increases in TNFalpha and MMP-1 production and collagen degradation suggests that collagenase cleavage of cartilage collagen is related to the activities of TNFalpha and MMP-1. The reduction in CII synthesis in early RA may contribute to the developing pathology, since a lack of synthesis of this molecule would inhibit maintenance of cartilage matrix.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14613270     DOI: 10.1002/art.11331

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  32 in total

1.  Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment.

Authors:  A W R van Kuijk; P Reinders-Blankert; T J M Smeets; B A C Dijkmans; P P Tak
Journal:  Ann Rheum Dis       Date:  2006-05-25       Impact factor: 19.103

Review 2.  Angiogenesis in psoriasis and psoriatic arthritis: clues to disease pathogenesis.

Authors:  Tai Teck Leong; Ursula Fearon; Douglas J Veale
Journal:  Curr Rheumatol Rep       Date:  2005-08       Impact factor: 4.592

3.  Human nasal cartilage responds to oncostatin M in combination with interleukin 1 or tumour necrosis factor alpha by the release of collagen fragments via collagenases.

Authors:  T G Morgan; A D Rowan; S C Dickinson; D Jones; A P Hollander; D Deehan; T E Cawston
Journal:  Ann Rheum Dis       Date:  2005-06-23       Impact factor: 19.103

4.  A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.

Authors:  A D Fraser; A W R van Kuijk; R Westhovens; Z Karim; R Wakefield; A H Gerards; R Landewé; S D Steinfeld; P Emery; B A C Dijkmans; D J Veale
Journal:  Ann Rheum Dis       Date:  2004-11-04       Impact factor: 19.103

Review 5.  A role for age-related changes in TGFbeta signaling in aberrant chondrocyte differentiation and osteoarthritis.

Authors:  Peter M van der Kraan; Esmeralda N Blaney Davidson; Wim B van den Berg
Journal:  Arthritis Res Ther       Date:  2010-01-29       Impact factor: 5.156

6.  IL-21 Enhances the Degradation of Cartilage Through the JAK-STAT Signaling Pathway During Osteonecrosis of Femoral Head Cartilage.

Authors:  Bin Chen; Yi Liu; Lei Cheng
Journal:  Inflammation       Date:  2018-03       Impact factor: 4.092

7.  Collagen biomarkers for arthritis applications.

Authors:  James D Birmingham; Vladimir Vilim; Virginia B Kraus
Journal:  Biomark Insights       Date:  2007-02-07

Review 8.  Cartilage homeostasis in health and rheumatic diseases.

Authors:  Mary B Goldring; Kenneth B Marcu
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

9.  Inflammatory mediators and cartilage biomarkers in synovial fluid after a single inflammatory insult: a longitudinal experimental study.

Authors:  Janny C de Grauw; Chris H A van de Lest; Paul René van Weeren
Journal:  Arthritis Res Ther       Date:  2009-03-09       Impact factor: 5.156

10.  Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis.

Authors:  Astrid Jüngel; Caroline Ospelt; Mark Lesch; Melissa Thiel; Teresa Sunyer; Olivier Schorr; Beat A Michel; Renate E Gay; Christoph Kolling; Craig Flory; Steffen Gay; Michel Neidhart
Journal:  Ann Rheum Dis       Date:  2009-06-03       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.